🔹 Oliver Hartmann, Acting Director General, AESGP
🔹 Oliver Hartmann, Acting Director General, AESGP
The value of switch: access, innovation and sustainability
🔹Jorge Batista, Senior Professional Affairs Advisor, PGEU
The value of switch: access, innovation and sustainability
🔹Jorge Batista, Senior Professional Affairs Advisor, PGEU
🔹 Olivér Várhelyi, Commissioner for Health and Animal Welfare
🔹 Olivér Várhelyi, Commissioner for Health and Animal Welfare
Building a proportionate evidence and benefit-risk
framework for switch
🔹Professor Eric P. Brass, M.D., Ph.D., UCLA
Building a proportionate evidence and benefit-risk
framework for switch
🔹Professor Eric P. Brass, M.D., Ph.D., UCLA
The value of switch: access, innovation and sustainability
🔹Professor Dr Uwe May, May & Bauer
The value of switch: access, innovation and sustainability
🔹Professor Dr Uwe May, May & Bauer
Building a proportionate evidence and benefit-risk
framework for switch
🔹Dr Sachin Silva, Principal, Global Advisory, IQVIA
Building a proportionate evidence and benefit-risk
framework for switch
🔹Dr Sachin Silva, Principal, Global Advisory, IQVIA
The value of switch: access, innovation and sustainability
🔹Jolanta Bilinska, Director and Treasurer, World Patients Alliance
The value of switch: access, innovation and sustainability
🔹Jolanta Bilinska, Director and Treasurer, World Patients Alliance
Interrupting your scroll today to remind you that prioritizing relaxation and self-care isn't a luxury, it's a necessity.
#nationalbathtubday #bathtubday #bathsoak #bubblebath #bathtime #vintagestyle #pinuphistory #retroart #classicpinup #pinupillustration #selfcareday
Interrupting your scroll today to remind you that prioritizing relaxation and self-care isn't a luxury, it's a necessity.
#nationalbathtubday #bathtubday #bathsoak #bubblebath #bathtime #vintagestyle #pinuphistory #retroart #classicpinup #pinupillustration #selfcareday
Building a proportionate evidence and benefit-risk
framework for switch
🔹Joshua Smith, Senior Manager Regulatory Affairs and Safety Strategy, Reckitt
Building a proportionate evidence and benefit-risk
framework for switch
🔹Joshua Smith, Senior Manager Regulatory Affairs and Safety Strategy, Reckitt
Building a proportionate evidence and benefit-risk
framework for switch
🔹Dr Martin Huber, Bfarm and Chair of the CMDh Non-Prescription Taskforce (HMA)
Building a proportionate evidence and benefit-risk
framework for switch
🔹Dr Martin Huber, Bfarm and Chair of the CMDh Non-Prescription Taskforce (HMA)
Panel discussion: the future of switch in Europe
🔹Jaume Pey, Director General, ANEFP (Spain)
Panel discussion: the future of switch in Europe
🔹Jaume Pey, Director General, ANEFP (Spain)
Panel discussion: the future of switch in Europe
🔹Spyros Sapounas, President of the National Organization for Medicines (EOF), Greece
Panel discussion: the future of switch in Europe
🔹Spyros Sapounas, President of the National Organization for Medicines (EOF), Greece
Making switch happen: practical pathways, case studies
and enablers
🔹André Ulmann, President, Cemag Care
Making switch happen: practical pathways, case studies
and enablers
🔹André Ulmann, President, Cemag Care
National experiences in advancing switch: initiatives,
programmes and lessons learned
🔹Thomas Dokios, General Director, EFEX (Greece)
National experiences in advancing switch: initiatives,
programmes and lessons learned
🔹Thomas Dokios, General Director, EFEX (Greece)
Making switch happen: practical pathways, case studies
and enablers
🔹Zeineb Lassoued, Global Regulatory Policy & Intelligence Lead, Opella
Making switch happen: practical pathways, case studies
and enablers
🔹Zeineb Lassoued, Global Regulatory Policy & Intelligence Lead, Opella
Making switch happen: practical pathways, case studies
and enablers
🔹Kristie Sourial, Global Switch Science Lead, Opella
Making switch happen: practical pathways, case studies
and enablers
🔹Kristie Sourial, Global Switch Science Lead, Opella
Making switch happen: practical pathways, case studies
and enablers
🔹Sabrina Pradeau, Category RA Lead - Women's Health & Global Switch, Perrigo
Making switch happen: practical pathways, case studies
and enablers
🔹Sabrina Pradeau, Category RA Lead - Women's Health & Global Switch, Perrigo
Panel discussion: the future of switch in Europe
🔹Serenella Cascio, Senior Director Regulatory Affairs Northern Europe, Skin & Essential Health Head, Kenvue
Panel discussion: the future of switch in Europe
🔹Serenella Cascio, Senior Director Regulatory Affairs Northern Europe, Skin & Essential Health Head, Kenvue
National experiences in advancing switch: initiatives,
programmes and lessons learned
🔹Luc Besançon, Director General, NèreS (France)
National experiences in advancing switch: initiatives,
programmes and lessons learned
🔹Luc Besançon, Director General, NèreS (France)
National experiences in advancing switch: initiatives,
programmes and lessons learned
🔹Lutz Boden, Managing Director OTC Market, Pharma Deutschland (Germany)
National experiences in advancing switch: initiatives,
programmes and lessons learned
🔹Lutz Boden, Managing Director OTC Market, Pharma Deutschland (Germany)
National experiences in advancing switch: initiatives,
programmes and lessons learned
🔹Michelle Riddalls OBE, CEO, PAGB (United Kingdom)
National experiences in advancing switch: initiatives,
programmes and lessons learned
🔹Michelle Riddalls OBE, CEO, PAGB (United Kingdom)
Panel discussion: the future of switch in Europe
🔹Sandra Monteiro, Infarmed and Chair of the EDQM Committee of Experts on the Classification of Medicines as Regards their Supply (CD-P-PH/PHO)
Panel discussion: the future of switch in Europe
🔹Sandra Monteiro, Infarmed and Chair of the EDQM Committee of Experts on the Classification of Medicines as Regards their Supply (CD-P-PH/PHO)